Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | FABP4 | P15090 | 3/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14917590 | 0.85 | EZH2 (0.48) | EZH2MGLLALDH1A1GAAKDM4E | |
| SCHEMBL16116199 | 0.83 | EZH2 (0.49) | EZH2MGLLNR4A2ALDH1A1CA12 | |
| SCHEMBL26265512 | 0.83 | EZH2 (0.46) | EZH2MGLLPTPN1CA12CA1 | |
| SCHEMBL6174526 | 0.81 | EZH2 (0.46) | EZH2MGLLALDH1A1CA12CA1 | |
| SCHEMBL27910227 | 0.78 | MGLL (0.38) | EZH2MGLLFABP4 | |
| Hydrochloric Acid SCHEMBL7884826 | 0.78 | EZH2 (0.43) | EZH2MGLL | |
| SCHEMBL2082208 | 0.78 | CA12 (0.52) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL17970375 | 0.78 | EZH2 (0.37) | EZH2MGLLPTPN1ALDH1A1CA12 | |
| SCHEMBL14727054 | 0.78 | EZH2 (0.40) | EZH2MGLLFABP4ALDH1A1GAA | |
| SCHEMBL1130987 | 0.77 | PTPN1 (0.61) | MGLLFABP4NR4A1NR4A2NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | LG CHEM, LTD. (KR) | 2024-03-28 | — | — | US | disclosed |
| EP-4242213-A1 | BORONIC ACID COMPOUND | Lg Chem, Ltd. (KR) | 2023-09-13 | — | — | EP | disclosed |
| CN-116568310-A | Boric acid compounds | 株式会社LG化学 | 2023-08-08 | — | — | CN | disclosed |
| US-11608347-B2 | Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-03-21 | — | — | US | disclosed |
| WO-2022123530-A1 | BORONIC ACID COMPOUND | 주식회사 엘지화학 | 2022-06-16 | — | — | WO | disclosed |
| US-20210024546-A1 | OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-01-28 | — | — | US | disclosed |
| EP-3737680-A1 | OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2020-11-18 | — | — | EP | disclosed |
| CN-111566105-A | Octahydropyrido [1, 2-alpha ] pyrazines as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2020-08-21 | — | — | CN | disclosed |
| WO-2019134985-A1 | OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-07-11 | — | — | WO | disclosed |
| WO-2014155301-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS INHIBITORS OF EZH2 | Piramal Enterprises Limited (IN) | 2014-10-02 | — | — | WO | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024546-A1 | OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS | PYM1, MAG, MAGI3 | EZH2 4276/4885MGLL 84/4885FABP4 4815/4885 |
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | EZH2 1258/4885MGLL 3038/4885FABP4 4705/4885 |
| US-11608347-B2 | Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitors | PYM1, MAG, MAGI3 | EZH2 4276/4885MGLL 84/4885FABP4 4815/4885 |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | PSMB11, PSMB1, BACH1 | EZH2 1566/4885MGLL 4444/4885FABP4 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.